A key U.S. House panel is considering legislation to dramatically expand studies on marijuana’s potential medical benefits for military veterans.
Filed by Veterans’ Affairs Committee GOP Chairman David Roe of Tennessee and Congressman Tim Walz of Minnesota, the top Democrat on the committee, the bill would encourage the U.S. Department of Veterans Affairs (VA) to “conduct and support research relating to the efficacy and safety” of medical cannabis “on the health outcomes of covered veterans diagnosed with chronic pain, post-traumatic stress disorder, and other conditions.”
22% of vets report using cannabis as a safer & more effective alternative to opioids & drug cocktails currently prescribed by VA for PTSD or chronic pain; yet, there has been a severe lack of research studying the full effect of #MedicinalCannabis on vets. https://t.co/4bkmZ97ix9
— Rep. Tim Walz (@RepTimWalz) April 17, 2018
Research would be done on full plant marijuana as well as extracts, and involve “at least three different strains of cannabis with significant variants in phenotypic traits and various ratios of tetrahydrocannabinol and cannabidiol in chemical composition.”
Studies would examine “varying methods of cannabis delivery, including topical application, combustible and noncombustible inhalation, and ingestion.”
It would require VA to preserve all data collected from the studies and issue a report to Congress within 180 days that includes a plan for implementation of research. The department would also have to send updates no less than annually for five years.
The panel’s Health Subcommittee will hold a hearing on the proposal on Tuesday afternoon.
Sen. Jon Tester (D-MT) plans to introduce a companion bill in the Senate.
While VA is already permitted to participate in cannabis research under current law, its leadership has been reluctant. Recently deposed Sec. David Shulkin, for example, repeatedly claimed in public remarks that Congress needs to act before the department